Shionogi Company Limited

Kentaro Asahi

Hiroyuki Kai

Yoshiyuki Taoda

Yukio Tada

Tsuyoshi Hasegawa

Takuya Shintani

Akira Iida

Hiroyuki Tobinaga

Takeshi Endoh

Yasuhiko Fujii

Tohru Horiguchi

Takayuki Kameyama

Miho Oohara

Toshikatsu Maki

Sae Jikihara

Ken'ichiroh Nakamura

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): whereinRand Rare taken together to form a bond; Rand Rand/or Rand Rare taken together to form oxo or the like; Ris hydrogen, substituted or unsubstituted alkyl or the like;Ris &#x2014;(CRR)&#x2014;R; Rand Rare hydrogen, substituted or unsubstituted alkyl or the like; Ris substituted or unsubstjtuted cycloalkyl or the like; n is an integer of 1 to 4; &#x2014;Ris &#x2014;X&#x2014;R; &#x2014;X&#x2014; is &#x2014;O&#x2014;, &#x2014;S&#x2014; or the like; Ris substituted or unsubstituted cycloalkyl or the like,or its pharmaceutically acceptable salt or a solvate thereof.

Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same

The present invention provides a novel P2Xand/or P2X/receptor antagonist. A compound represented by the formula (I): wherein Zis optionally protected hydroxy, etc.; Zis &#x2014;C(&#x2550;O)&#x2014;, etc.; Zand Zare taken together &#x2550;O or &#x2550;S; t is an integer of 0 to 4; Rand Rare each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; Rand Rare each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; Ris substituted or unsubstituted alkyl, etc.; Ris substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.

Pyrolinone derivative and pharmaceutical composition comprising the same

Growing community of inventors

Toyonaka, Japan

Kentaro Asahi